Evaluating a new treatment for stroke using a lipoxygenase inhibitor.
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network
['FUNDING_U01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11080961
This study is looking at a new drug called BPN-27332 to see if it can help reduce brain damage and improve recovery after a stroke, and it's being tested in lab animals to compare its effects with current stroke treatments.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11080961 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of a novel drug, BPN-27332, which inhibits the 12/15 lipoxygenase enzyme, in treating ischemic stroke in preclinical rodent models. The study aims to compare this treatment with existing stroke therapies under controlled laboratory conditions. By targeting the enzyme that contributes to neuronal cell death and blood-brain barrier damage, the research seeks to determine if BPN-27332 can reduce brain damage and improve recovery outcomes. The findings could lead to new therapeutic options for stroke patients if successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced an ischemic stroke and are seeking new treatment options.
Not a fit: Patients who have not experienced a stroke or those with hemorrhagic stroke may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly reduces brain damage and improves recovery for stroke patients.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting the 12/15 lipoxygenase enzyme, indicating potential for success.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VAN LEYEN, KLAUS — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: VAN LEYEN, KLAUS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: adult onset diabetes, Adult-Onset Diabetes Mellitus